Quarterly report
Open the filing on sec.gov
MiNK Therapeutics, Inc. (INKT)
Nasdaq: INKT · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenuen/a
Net income-$12.5M-15.9%
Earnings per share$-2.93-2.4%
Operating cash flow-$5.9M+38.0%
Cash$13.4M+191.9%
Debtn/a
Shareholders’ equity-$14.2M+27.4%
Shares, diluted4,270,470+13.2%
Return on equityn/a
The recordfrom its filings
Filings in 202639
Newest filingNov 12 · 10-Q
Annual reportMar 31, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$100,000
Insider buys, 12 months$0.00
Patents granted4
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$11.0MCash from operations -$7.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.